Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) EBITDA Margin (2016 - 2026)

Champions Oncology has reported EBITDA Margin over the past 17 years, most recently at 1.67% for Q1 2026.

  • For Q1 2026, EBITDA Margin fell 2807.0% year-over-year to 1.67%; the TTM value through Jan 2026 reached 4.53%, down 1526.0%, while the annual FY2025 figure was 8.0%, 2266.0% up from the prior year.
  • EBITDA Margin for Q1 2026 was 1.67% at Champions Oncology, down from 1.23% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 26.4% in Q1 2025 and troughed at 21.44% in Q1 2024.
  • A 5-year average of 4.5% and a median of 2.07% in 2022 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: surged 4785bps in 2025 and later plummeted -2807bps in 2026.
  • Year by year, EBITDA Margin stood at 0.05% in 2022, then tumbled by -34564bps to 16.89% in 2023, then skyrocketed by 132bps to 5.43% in 2024, then tumbled by -77bps to 1.23% in 2025, then plummeted by -235bps to 1.67% in 2026.
  • Business Quant data shows EBITDA Margin for CSBR at 1.67% in Q1 2026, 1.23% in Q4 2025, and 3.77% in Q3 2025.